Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience

Maha M. Islami; Mansoor Ahmed Khan; Mohammed A. Aseeri; Majed A. Alshamrani; Abdelmajid Alnatsheh; Sameer Alamoudi; Ahmed A. Alzahrani

doi:10.12659/AOT.938585

03 March 2023: Original Paper

Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience

Maha M. Islami ^1CDE* , Mansoor Ahmed Khan ^23ABCDEF , Mohammed A. Aseeri ^23A , Majed A. Alshamrani ^23E , Abdelmajid Alnatsheh ^23ACDE , Sameer Alamoudi ^34ADE , Ahmed A. Alzahrani ^5E

DOI: 10.12659/AOT.938585

Ann Transplant 2023; 28:e938585

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 2 Amount of CD34+ cells in allogenic SCT. Created using SPSS software version 23.

Back to the Article

Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience

Your Privacy